Literature DB >> 10819365

Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase.

I Bedrosian1, M B Faries, D Guerry, R Elenitsas, L Schuchter, R Mick, F R Spitz, L P Bucky, A Alavi, D E Elder, D L Fraker, B J Czerniecki.   

Abstract

BACKGROUND: Patients with thin primary melanomas (< or = 1 mm) generally have an excellent prognosis. However, the presence of a vertical growth phase (VGP) adversely impacts the survival rate. We report on the rate of occurrence of nodal metastasis in patients with thin primary melanomas with a VGP who are offered sentinel lymph node (SLN) biopsy.
METHODS: Among 235 patients with clinically localized cutaneous melanomas who underwent successful SLN biopsy, 71 had lesions 1 mm or smaller with a VGP. The SLN was localized by using blue dye and a radiotracer. If negative for tumor by using hematoxylin and eosin staining, the SLN was further examined by immunohistochemistry.
RESULTS: The rate of occurrence of SLN metastasis was 15.2% in patients with melanomas deeper than 1 mm and 5.6% in patients with thin melanomas. Three patients with thin melanomas and a positive SLN had low-risk lesions, based on a highly accurate six-variable multivariate logistic regression model for predicting 8-year survival in stage I/II melanomas. The fourth patient had a low- to intermediate-risk lesion based on this model. At the time of the lymphadenectomy, one patient had two additional nodes with metastasis.
CONCLUSIONS: VGP in a melanoma 1 mm or smaller seems to be a risk factor for nodal metastasis. The risk of nodal disease may not be accurately predicted by the use of a multivariate logistic regression model that incorporates thickness, mitotic rate, regression, tumor-infiltrating lymphocytes, sex, and anatomical site. Patients with thin lesions having VGP should be evaluated for SLN biopsy and trials of adjuvant therapy when stage III disease is found.

Entities:  

Mesh:

Year:  2000        PMID: 10819365     DOI: 10.1007/s10434-000-0262-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  25 in total

Review 1.  Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Authors:  Jun Guo; Shukui Qin; Jun Liang; Tongyu Lin; Lu Si; Xiaohong Chen; Zhihong Chi; Chuanliang Cui; Nan Du; Yun Fan; Kangsheng Gu; Fang Li; Junling Li; Yongheng Li; Houjie Liang; Jiwei Liu; Man Lu; Aiping Lu; Kejun Nan; Xiaohui Niu; Hongming Pan; Guoxin Ren; Xiubao Ren; Yongqian Shu; Xin Song; Min Tao; Baocheng Wang; Wenbin Wei; Di Wu; Lingying Wu; Aiwen Wu; Xiaolin Xu; Junyi Zhang; Xiaoshi Zhang; Yiping Zhang; Huiyan Zhu
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

3.  Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma.

Authors:  Maxine C Dudek; Kaitlyn E Wong; Lotfi M Bassa; Maria Carmen Mora; Jennifer Ser-Dolansky; Jean M Henneberry; Giovanna M Crisi; Richard B Arenas; Sallie S Schneider
Journal:  Tumour Biol       Date:  2015-07-10

4.  WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway.

Authors:  Yumei Li; Yu Zhou; Bifei Li; Fan Chen; Weiyu Shen; Yusheng Lu; Chunlian Zhong; Chen Zhang; Huanzhang Xie; Vladimir L Katanaev; Lee Jia
Journal:  Oncogene       Date:  2020-01-31       Impact factor: 9.867

Review 5.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

6.  The melanocyte differentiation program predisposes to metastasis after neoplastic transformation.

Authors:  Piyush B Gupta; Charlotte Kuperwasser; Jean-Philippe Brunet; Sridhar Ramaswamy; Wen-Lin Kuo; Joe W Gray; Stephen P Naber; Robert A Weinberg
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

7.  Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.

Authors:  Uma N M Rao; Sandra J Lee; Weixiu Luo; Martin C Mihm; John M Kirkwood
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

Review 8.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

9.  Targeting the cyclin-dependent kinase 5 in metastatic melanoma.

Authors:  Samanta Sharma; Tian Zhang; Wojciech Michowski; Vito W Rebecca; Min Xiao; Roberta Ferretti; Jan M Suski; Roderick T Bronson; Joao A Paulo; Dennie Frederick; Anne Fassl; Genevieve M Boland; Yan Geng; Jacqueline A Lees; Rene H Medema; Meenhard Herlyn; Steven P Gygi; Piotr Sicinski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-19       Impact factor: 11.205

10.  Melanoma miRNA trafficking controls tumour primary niche formation.

Authors:  Shani Dror; Laureen Sander; Hila Schwartz; Danna Sheinboim; Aviv Barzilai; Yuval Dishon; Sebastien Apcher; Tamar Golan; Shoshana Greenberger; Iris Barshack; Hagar Malcov; Alona Zilberberg; Lotan Levin; Michelle Nessling; Yael Friedmann; Vivien Igras; Ohad Barzilay; Hananya Vaknine; Ronen Brenner; Assaf Zinger; Avi Schroeder; Pinchas Gonen; Mehdi Khaled; Neta Erez; Jörg D Hoheisel; Carmit Levy
Journal:  Nat Cell Biol       Date:  2016-08-22       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.